Methods for preserving the viability of retinal ganglion cells in patients with glaucoma by an anti-TNF receptor 2 (anti-TNFR2) antibody
The invention provides a method of preserving ocular cells in a patient having or at risk of developing glaucoma. In particular, microglial cell activation can be decreased, oligodendrocyte loss can be reduced, and/or the viability of retinal ganglion cells can be preserved by administering a selective TNFR2 antagonist to an individual having or at risk of developing glaucoma.
1. A method for preserving the viability of a retinal ganglion cell in a patient having or at risk of developing glaucoma, the method comprising administering in an amount sufficient to preserve the viability of a retinal ganglion cell in the patient a substance that selectively binds to TNF Receptor 2 (TNFR2) and blocks binding of TNFα thereto, wherein the substance is an anti-TNFR2 antibody.
2. The method of claim 1 , wherein the anti-TNFR2 antibody is a monoclonal anti-TNFR2 antibody.
3. A method for preserving the viability of a retinal ganglion cell in a patient having or at risk of developing glaucoma, the method consisting essentially of administering a selective TNF Receptor 2 (TNFR2) antagonist in an amount sufficient to preserve the viability of a retinal ganglion cell in the patient, wherein the TNFR2 antagonist is an anti-TNFR2 antibody.
4. The method of claim 3 , wherein the anti-TNFR2 antibody is a monoclonal anti-TNFR2 antibody.
5. A method for preserving the viability of a retinal ganglion cell in a patient having or at risk of developing glaucoma, the method comprising administering a selective TNF Receptor 2 (TNFR2) antagonist in an amount sufficient to preserve the viability of a retinal ganglion cell in the patient, wherein the TNFR2 antagonist is an anti-TNFR2 antibody.
6. The method of claim 5 , wherein the anti-TNFR2 antibody is a monoclonal anti-TNFR2 antibody.